ACEM Celebrates 41th anniversary of the re-establishment: World-Class Disciplines Drive Top Global Rankings at SJTU
SHANGHAI, June 16, 2025 /PRNewswire/ -- The year 2025 marked the 41th anniversary of the re-establishment of Antai College of Economics and Management (ACEM), Shanghai Jiao Tong University (SJTU). ACEM made remarkable achievements in discipline development, academic research, industry research, and exchanges and cooperation.
ACEM ranked the world's 5th in the FT Masters in Management latest Ranking and the world's 1st in employment. Five of its disciplines ranked among the global top 50, with 'Business & Management Studies""Statistics & Operational Research' in the top 30 of the 2025 QS World University Rankings by Subject. In World University Rankings 2025 by subject: Business and Economics, ACEM ranked 25th globally and 3rd in China. The MBA program was among the top three in Chinese Mainland for six consecutive years in QS Global MBA Rankings.
The educational programs of ACEM further expanded. ACEM entered into a cooperative agreement with CUHK to launch a dual-degree program in Finance and FinTech, the first of its kind between universities in Chinese mainland and Hong Kong. ACEM also further built platforms and deepened cooperation with top-notch universities such as Columbia University, Tsinghua University, and Chinese University of Hong Kong as well as benchmark companies such as CATL and Bank of China (BOC) to create new driving forces for industry-university-research collaborative development. In 2024 ACEM established three new research institutes, entered into an agreement with CATL to jointly build the 21st Century Institute for Global Enterprise, and launched the SJTU Institute for Intelligent Computing (IIC) and the Environmental, Social and Governance Research Institute.
'ACEM have embarked on the next phase of development, the journey to the top. The center of our strategy is to promote industry research. The future Antai will have not only academic field experts but also industry experts.' says by Chen Frangruo, Dean of ACEM.
View original content to download multimedia: https://www.prnewswire.com/news-releases/acem-celebrates-41th-anniversary-of-the-re-establishment-world-class-disciplines-drive-top-global-rankings-at-sjtu-302482223.html
SOURCE Antai College of Economics and Management, Shanghai Jiao Tong University
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- SHANGHAI, June 17, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase I clinical trial evaluating SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) respiratory combination vaccine candidates based on prefusion-stabilized F (PreF)-Trimer subunit vaccine antigens utilizing Clover's Trimer-Tag vaccine technology platform. "We are pleased to announce the Phase I clinical trial initiation of our potential first-in-class combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), further demonstrating the differentiated value of our validated Trimer-Tag platform," said Joshua Liang, Chief Executive Officer & Board Director of Clover. "While currently approved protein-based RSV vaccines are safe & effective, critical gaps persist globally, including the inability to prevent significant respiratory disease burden caused by other viruses related to RSV such as human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3). Thus, we look forward to the clinical trial results for our respiratory combination vaccine candidates in order to maximize our impact on public health globally." In October 2024, Clover announced Phase I results in 70 older adults (60-85 years) for Clover's non-adjuvanted RSV PreF vaccine candidate (SCB-1019) compared head-to-head to GSK's AS01E-adjuvanted RSV vaccine (AREXVY), and results indicated a potential best-in-class combined immunogenicity & tolerability profile of SCB-1019. These results supported the further development and evaluation of SCB-1019 in combination with the PreF-Trimer antigens for hMPV and PIV3, which are also utilizing the Trimer-Tag platform. The ongoing Phase I trial for Clover's combination vaccine candidates is enrolling up to 192 older adults (60-85 years), and the participants will be randomized to receive either SCB-1022 (RSV+hMPV), SCB-1033 (RSV+hMPV+PIV3) or SCB-1019 (RSV) comparator. The study will assess safety, reactogenicity and immunogenicity. About Clover Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. Clover Forward-looking Statements This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time. View original content: SOURCE Clover Biopharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Undiscovered Gems in Asia to Explore This June 2025
As geopolitical tensions in the Middle East and trade-related concerns weigh on global markets, Asian stocks present a unique landscape of opportunities. With small-cap indices experiencing volatility, discerning investors may find potential in lesser-known companies that demonstrate resilience and innovation amidst changing economic conditions. Name Debt To Equity Revenue Growth Earnings Growth Health Rating Toho 72.03% 6.01% 64.19% ★★★★★★ Yashima Denki 2.40% 0.14% 21.00% ★★★★★★ FALCO HOLDINGS 4.93% -0.16% 1.44% ★★★★★★ Hefei Gocom Information TechnologyLtd NA 9.11% -12.23% ★★★★★★ Center International GroupLtd 18.20% 0.69% -31.63% ★★★★★★ ISE Chemicals 1.40% 15.34% 32.61% ★★★★★★ Shanghai SK Automation TechnologyLtd 37.27% 33.22% 12.18% ★★★★★☆ Guangdong Transtek Medical Electronics 18.14% -7.58% -3.26% ★★★★★☆ Daoming Optics&ChemicalLtd 33.83% 1.38% 5.82% ★★★★★☆ ITCENGLOBAL 66.11% 16.65% 1.99% ★★★★★☆ Click here to see the full list of 2614 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Value Rating: ★★★★★★ Overview: Snt Dynamics Ltd. engages in the manufacturing and sale of precision machinery, with a market capitalization of ₩1.25 trillion. Operations: Snt Dynamics Ltd. generates revenue primarily from its Machinery Business and Transportation Equipment Business, with the latter contributing significantly more at ₩672.52 billion compared to the former's ₩2.88 billion. Snt Dynamics Ltd. stands out in the aerospace and defense sector with a robust 96% earnings growth over the past year, surpassing industry averages. Despite its small size, this debt-free company boasts a favorable price-to-earnings ratio of 12.4x, slightly undercutting the KR market's 12.6x benchmark. Recent financials reveal net income at KRW 17,769 million for Q1 2025, up from KRW 12,880 million last year. The firm announced a private placement to issue bonds worth KRW 110 billion which are fully exchangeable into shares starting July 2025; such strategic moves may bolster future growth prospects significantly. Get an in-depth perspective on Snt DynamicsLtd's performance by reading our health report here. Evaluate Snt DynamicsLtd's historical performance by accessing our past performance report. Simply Wall St Value Rating: ★★★★★☆ Overview: Daou Technology Inc., along with its subsidiaries, offers IT and finance services and has a market capitalization of approximately ₩1.42 trillion. Operations: Daou Technology Inc. generates revenue primarily from its finance segment, with significant contributions from the Finance - Wholesale General Manager (₩8.22 billion) and Finance - Retail General Manager (₩2.52 billion) divisions. The non-financial segment includes System Construction, which adds ₩452.49 million to the revenue stream. Daou Technology, a noteworthy player in the tech sector, has shown impressive financial strides. With earnings growth of 76.1% over the past year, it outpaced its industry peers significantly. The company reported sales of KRW 21.28 billion for Q1 2025, up from KRW 12.50 billion last year, though net income slightly dipped to KRW 102.11 million from KRW 103.12 million previously. Despite not being free cash flow positive, Daou's interest payments are well-covered by EBIT at a robust rate of 97 times coverage and its debt-to-equity ratio improved from over five years to stand at a healthier level today. Dive into the specifics of Daou Technology here with our thorough health report. Assess Daou Technology's past performance with our detailed historical performance reports. Simply Wall St Value Rating: ★★★★☆☆ Overview: Gallant Micro. Machining Co., Ltd. specializes in the production and sale of machinery, equipment, precision molds, and various components across Taiwan, China, and international markets with a market cap of NT$16.65 billion. Operations: Gallant Micro. Machining Co., Ltd. generates revenue primarily from its machinery and equipment segment, with NT$1.81 billion attributed to this area, supplemented by contributions from KMC Corporation at NT$755.95 million. Gallant Micro. Machining, a small player in the semiconductor space, has shown impressive earnings growth of 40.9% over the past year, outpacing the industry's 10.8%. Despite this growth, their recent Q1 2025 results reported a drop in sales to TWD 430.22 million from TWD 695.32 million and net income to TWD 45.84 million from TWD 139.36 million year-over-year, reflecting challenges amid volatility in share prices over three months. The debt-to-equity ratio has increased significantly from 44% to 91%, though with a satisfactory net debt level at just over 13%, interest coverage remains solid and non-cash earnings are high. Click here and access our complete health analysis report to understand the dynamics of Gallant Micro. Machining. Examine Gallant Micro. Machining's past performance report to understand how it has performed in the past. Investigate our full lineup of 2614 Asian Undiscovered Gems With Strong Fundamentals right here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A003570 KOSE:A023590 and TPEX:6640. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Washington Post
an hour ago
- Washington Post
Oil prices rise and US futures fall as Israel urges residents of Iran's capital to evacuate
BANGKOK — Oil prices resumed their upward climb and U.S. futures were lower early Tuesday after Israel's military issued an evacuation warning to 330,000 people in Iran's capital Tehran. Asian shares were mixed. The evacuation warning was for a part of Tehran, a city of 9.5 million, that houses the country's state TV and police headquarters and three large hospitals, including one owned by Iran's paramilitary Revolutionary Guard. U.S. President Donald Trump announced he was returning from the G7 summit in Canada a day early due to the intensifying conflict. The futures for the S&P 500 and the Dow Jones Industrial Average were down 0.3%. In Asia, Tokyo's Nikkei 225 index climbing 0.6% to 38,547.56 as the Japanese central bank opted to keep its key interest rate unchanged at 0.5%. The Bank of Japan has been gradually raising its rate from near zero and cutting back on its purchases of Japanese government bonds and other assets to help counter inflation. It said economic growth was likely to moderate and there was some weakness in consumer sentiment, housing investment. 'In particular, it is extremely uncertain how trade and policies in each jurisdiction will evolve and how overseas activity and prices will react to them,' the BOJ's statement said. Chinese shares edged lower. In Hong Kong, the Hang Seng slipped 0.1% to 24,038.56. The Shanghai Composite index declined 0.2% to 3,382.14. In South Korea, the Kospi gained 0.4% to 2,956.88. Australia's S&P/ASX 500 gave up 0.1% to 8,543.60. Taiwan's Taiex gained 0.6% and in Bangkok the SET was little changed. As Israel and Iran attack each other the fear remains that a wider war could constrict the flow of Iran's oil to its customers. That in turn could raise gasoline prices worldwide and keep them high, though spikes in prices from previous conflicts have been brief. Crude jumped 7% late last week after Israel's attack on Iranian nuclear and military targets . Early Tuesday, U.S. benchmark crude oil gained 31 cents to $72.08 per barrel, while Brent crude, the international standard, was up 33 cents at $73.56 per barrel. On Monday, the mood was calm on Wall Street, as the S&P 500 climbed 0.9% to reclaim most of its drop from Friday . It closed at 6,033.11. The Dow Jones Industrial Average added 0.8% to 42,515.09, and the Nasdaq composite gained 1.5% to 19,701.21. U.S. Steel rose 5.1% after Trump signed an executive order on Friday paving the way for an investment in the company by Japan's Nippon Steel. Trump would have unique influence over the operations of U.S. Steel under the terms of the deal. They helped offset drops for defense contractors, which gave back some of their jumps from Friday. Lockheed Martin fell 4%, and Northrop Grumman sank 3.7%. The price of gold receded after jumping on Friday, when investors were looking for someplace safe to park their cash . An ounce of gold fell $14.60 to $3,402.40 per ounce. Investors have other concerns, key among them Donald Trump's tariffs , which still threaten to slow the U.S. economy and raise inflation if Washington doesn't win trade deals with other countries. The specter of tariffs was looming over the meeting of the Group of Seven meeting of major economies in Canada. Later this week, the Federal Reserve is set to discuss whether to lower or raise interest rates, with the decision due on Wednesday. The nearly unanimous expectation among traders and economists is that the Fed will stand pat. The Federal Reserve has hesitated to lower interest rates after one cut late last year. It is waiting to see how much Trump's tariffs will hurt the economy and raise inflation , which has remained tame recently, and is near the Fed's 2% target. More important for financial markets on Wednesday will likely be forecasts for where Fed officials they see the economy and interest rates heading in upcoming years. In other dealings early Tuesday, the U.S. dollar fell to 144.59 Japanese yen from 144.75 yen. The euro rose to $1.1564 from $1.1562. ___ AP Business Writer Stan Choe contributed.
